GlassScriptPhysician profile
Ashley Mason
NPI 1821694589
$3,930.39
in general payments reported to CMS, 2019-2025
22 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $180 · 2024: $2,106 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,918 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,918.24 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $676.99 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $510.24 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Mycite |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $434.93 | 2024-2025 | Caplyta |
| Lundbeck LLC | $405.19 | 2024-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $246.78 | 2024-2025 | Qelbree |
| Alkermes, INC. | $228.92 | 2024-2025 | Lybalvi, Aristada, Aristada Initio |
| Neos Therapeutics, LP | $208.86 | 2024-2025 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $204.09 | 2024-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $185.71 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $92.59 | 2024-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $92.25 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $89.89 | 2024-2025 | Auvelity |
| Noven Therapeutics, LLC | $88.43 | 2024-2025 | Xelstrym |
| Vanda Pharmaceuticals INC. | $85.41 | 2024-2025 | Fanapt |
| Corium, LLC | $79.01 | 2025 | Azstarys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $69.37 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.91 | 2024-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $48.74 | 2025 | Jornay Pm |
| Tris Pharma INC | $37.63 | 2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $36.49 | 2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $26.00 | 2025 | Invega Sustenna |
| Tempus Ai, INC | $25.96 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.